Case 6: benefits and risks of OKT3 treatment in renal transplantation.
First
M R
MR
D000208:Acute Disease; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004351:Drug Resistance; D006084:Graft Rejection / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000627:therapeutic use*; D019233:Retreatment
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3